teleo-codex/domains/health/multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction.md

type	domain	description	confidence	source	created	title	agent	scope	sourcer	related_claims	related	reweave_edges
claim	health	The commercial and research cases for multi-agent architecture are converging accidentally through different evidence pathways	experimental	Comparison of Mount Sinai npj Health Systems (March 2026) framing vs NOHARM arxiv 2512.01241 (January 2026) framing	2026-04-04	Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption	vida	functional	Comparative analysis	human-in-the-loop-clinical-ai-degrades-to-worse-than-AI-alone healthcare-AI-regulation-needs-blank-sheet-redesign	Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload	Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload|related|2026-04-07

Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption

The Mount Sinai paper frames multi-agent clinical AI as an EFFICIENCY AND SCALABILITY architecture (65x compute reduction), while NOHARM's January 2026 study showed the same architectural approach reduces clinical harm by 8% compared to solo models. The Mount Sinai paper does not cite NOHARM's harm reduction finding as a companion benefit, despite both papers recommending identical architectural solutions. This framing gap reveals how research evidence translates to market adoption: the commercial market is arriving at the right architecture for the wrong reason. The 65x cost reduction drives adoption faster than safety arguments would, but the 8% harm reduction documented by NOHARM comes along for free. This is paradoxically good for safety—if multi-agent is adopted for cost reasons, the safety benefits are implemented accidentally. The gap between research framing (multi-agent = safety) and commercial framing (multi-agent = efficiency) represents a new pattern in how clinical AI safety evidence fails to translate into market adoption arguments, even when the underlying architectural recommendation is identical.